Tyra Biosciences, Inc. (TYRA): EBITDA
-$132.22M
Year ended 2025-12-31
-$159.92M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$132.22M | n/m | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | -$103.66M | n/m | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | -$79.59M | n/c | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | -$58.63M | n/m | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | -$26.15M | n/m | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | -$9.25M | n/a | 2022-03-03, From 2020-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | 2025-12-31 | -$132.22M | n/m |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | -$80.76M | n/m |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | -$58.89M | n/m |
| Nektar Therapeutics (NKTR) | 2025-12-31 | -$139.08M | n/m |
| Annexon, Inc. (ANNX) | 2025-12-31 | -$214.24M | n/m |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | -$123.80M | n/m |
| Neurogene Inc. (NGNE) | 2025-12-31 | -$100.28M | n/m |
| Contineum Therapeutics, Inc. (CTNM) | 2025-12-31 | -$67.74M | n/m |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | 2025-12-31 | -$152.07M | n/m |
Compare TYRA, ENTA, ZVRA, NKTR side by side · Screen every company in Pharmaceutical Preparations ↗